Lilly’s weight-loss drug reduces sleep apnea severity in late-stage trials
![Lilly’s weight-loss drug reduces sleep apnea severity in late-stage trials](https://nypost.com/wp-content%2Fuploads%2Fsites%2F2%2F2024%2F04%2Fnewspress-collage-g3if7incx-1713465504749.jpg?quality%3D90%26strip%3Dall%261713451165)
Eli Lilly (LLY.N), opens new tab said on Wednesday its weight-loss drug helped reduce episodes of irregular breathing associated with a common sleep-related disorder in two late-stage trials, paving the way for expanding use of the drug.